Home/Magenta Therapeutics/Michael Bell, Ph.D.

MB

Michael Bell, Ph.D.

Co-founder, former CSO

Magenta Therapeutics

Therapeutic Areas

Autoimmune Diseases Blood Cancers Genetic Diseases

Magenta Therapeutics Pipeline

Drug	Indication	Phase
MGTA-117	Conditioning for AML/MDS transplant	Phase 1/2
MGTA-145 + plerixafor	Stem cell mobilization	Phase 2

Leadership Team at Magenta Therapeutics

Jason Gardner, D.Phil.

Co-founder, President & CEO

Michael A. Narachi

Former Chairman of the Board

View full Magenta Therapeutics profile